Current advances in the diagnosis and personalized treatment of breast cancer: lessons from tumor biology

被引：8
作者：
Kern, Rodrigo [1 ,2 ]
Correa, Stephany Christiane [3 ]
Scandolara, Thalita Basso [1 ,4 ]
da Silva, Janaina Carla [1 ,2 ]
Pires, Bruno Ricardo [5 ,6 ]
Panis, Carolina [1 ,2 ]
机构：
[1] State Univ West Parana, Lab Tumor Biol, BR-85601970 Francisco Beltrao, Parana, Brazil
[2] State Univ West Parana, Postgrad Program Hlth Appl Sci, BR-85601970 Francisco Beltrao, Parana, Brazil
[3] Natl Canc Inst INCA, Ctr Bone Marrow Transplantat, Lab Stem Cells, BR-20230130 Rio De Janeiro, RJ, Brazil
[4] Univ Fed Rio de Janeiro, BR-21941901 Rio De Janeiro, RJ, Brazil
[5] Inst Nacl Canc Jose Alencar Gomes da Silva, BR-20230130 Rio De Janeiro, RJ, Brazil
[6] Univ Ottawa, Dept Cellular & Mol Med, Ottawa, ON, Canada
来源：
PERSONALIZED MEDICINE | 2020年 / 17卷 / 05期
关键词：
biomarkers; breast cancer; genomic profile; immune checkpoints inhibitors; multigene arrays; personalized treatment; prognosis; therapy development; tumor biology; RANDOMIZED PHASE-II; INTERNATIONAL EXPERT CONSENSUS; PLACEBO PLUS FULVESTRANT; ESTROGEN-RECEPTOR; GENE-EXPRESSION; DOUBLE-BLIND; CTLA-4; BLOCKADE; INFILTRATING LYMPHOCYTES; POSTMENOPAUSAL WOMEN; TAXANE-ANTHRACYCLINE;
D O I：
10.2217/pme-2020-0070
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Breast cancer treatment has advanced enormously in the last decade. Most of this is due to advances reached in the knowledge regarding tumor biology, mainly in the field of diagnosis and treatment. This review brings information about how the genomics-based information contributed to advances in breast cancer diagnosis and prognosis perspective, as well as presents how tumor biology discoveries fostered the main therapeutic approaches available to treat such patients, based on a personalized point of view.
引用
收藏
页码：399 / 420
页数：22
相关论文
共 165 条
[11]  
[Anonymous], 2019, J CLIN ONCOL S
[12]  
[Anonymous], 2002, Genomics and World Health: report of the advisory committee on health research
[13]  
[Anonymous], J CLIN ONCOL S
[14]   A meta-analysis of oestrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 discordance between primary breast cancer and metastases [J].
Aurilio, Gaetano ;
Disalvatore, Davide ;
Pruneri, Giancarlo ;
Bagnardi, Vincenzo ;
Viale, Giuseppe ;
Curigliano, Giuseppe ;
Adamoli, Laura ;
Munzone, Elisabetta ;
Sciandivasci, Angela ;
De Vita, Fernando ;
Goldhirsch, Aron ;
Nole, Franco .
EUROPEAN JOURNAL OF CANCER, 2014, 50 (02) :277-289
[15]   Cancer stem cell in breast cancer therapeutic resistance [J].
Bai, Xupeng ;
Ni, Jie ;
Beretov, Julia ;
Graham, Peter ;
Li, Yong .
CANCER TREATMENT REVIEWS, 2018, 69 :152-163
[16]   Restoring function in exhausted CD8 T cells during chronic viral infection [J].
Barber, DL ;
Wherry, EJ ;
Masopust, D ;
Zhu, BG ;
Allison, JP ;
Sharpe, AH ;
Freeman, GJ ;
Ahmed, R .
NATURE, 2006, 439 (7077) :682-687
[17]  
Bartlett JMS, 2016, JNCI-J NATL CANCER I, V108, P1, DOI DOI 10.1093/JNCI/DJW05
[18]   Phase III study of taselisib (GDC-0032) + fulvestrant (FULV) v FULV in patients (pts) with estrogen receptor (ER)-positive, PIK3CA-mutant (MUT), locally advanced or metastatic breast cancer (MBC): Primary analysis from SANDPIPER. [J].
Baselga, Jose ;
Dent, Susan Faye ;
Cortes, Javier ;
Im, Young-Hyuck ;
Dieras, Veronique ;
Harbeck, Nadia ;
Krop, Ian E. ;
Verma, Sunil ;
Wilson, Timothy R. ;
Jin, Huan ;
Wang, Lijia ;
Schimmoller, Frauke ;
Hsu, Jerry Y. ;
He, Jing ;
DeLaurentiis, Michelino ;
Drullinsky, Pamela ;
Jacot, William .
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (18)
[19]   Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial [J].
Baselga, Jose ;
Im, Seock-Ah ;
Iwata, Hiroji ;
Cortes, Javier ;
De laurentiis, Michele ;
Jiang, Zefei ;
Arteaga, Carlos L. ;
Jonat, Walter ;
Clemons, Mark ;
Ito, Yoshinori ;
Awada, Ahmad ;
Chia, Stephen ;
Jagiello-Gruszfeld, Agnieszka ;
Pistilli, Barbara ;
Tseng, Ling-Ming ;
Hurvitz, Sara ;
Masuda, Norikazu ;
Takahashi, Masato ;
Vuylsteke, Peter ;
Hachemi, Soulef ;
Dharan, Bharani ;
Di Tomaso, Emmanuelle ;
Urban, Patrick ;
Massacesi, Cristian ;
Campone, Mario .
LANCET ONCOLOGY, 2017, 18 (07) :904-916
[20]  
Beaver JA, 2012, FUTURE ONCOL, V8, P651, DOI [10.2217/FON.12.49, 10.2217/fon.12.49]
12345678910